You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
SharePoint
Follow
Menu
For Patients & Visitors
NUHS App
Appointments
Find a Doctor
Find Directions
Our Facilities
What to Expect For Your First Visit
TeleConsult
Charges & Payment
Chemotherapy Bill Estimates
Total Bill Estimates & Benchmarks
For International Patients
Home & Community Programmes
Cancer Survivorship
Patient Support Groups
NCIS Dream Makers
Join a Research Study
COVID-19 Vaccination & Patients with Cancer
For Healthcare Professionals
Make a Referral
GP Liaison Centre
Research
Education
SPARK Newsletter
Journals and Publications
Our Services
Specialties
NCIS Treatment Approach
NCIS Specialised Programmes
NCIS Scalp Cooling Therapy
Geriatric Oncology
Home & Community Programmes
NCIS Home Care Programme
NCIS on the Go Programme
Follow Up Cancer Care in the Community
Cancer Survivorship
Patient Support Groups
NCIS Dream Makers
Research & Education
Haematology-Oncology Research Group (HORG)
Clinical Trials
FAQ on Clinical Trials
HORG Programmes & Services
Education
Cancer Information
About Cancer
Cancer Trends
Cancer Screening
Chemotherapy Resources
NCIS Stories of Hope
Caregiver Information
Health Tips to Manage Your Risk of Cancer
Nutrition for Cancer Patients
Brochures
Videos
Events
Events & Registration
NCIS Annual Research Meeting (NCAM)
Breast Cancer Awareness Month
NCIS International Surgical Oncology Symposium
NCIS Celebrates Life
Give a Gift
NCIS Cancer Fund
Donate Now
NCIS Honour Roll of Donors
Donating to Research
Collaboration and Corporate Sponsorship
NCIS Cancer Fund Donor Report
About NCIS
Overview
A Member of NUHS
Our Vision, Mission, Values
At the Helm
Milestones, Achievements & Awards
Clinical and Treatment Outcomes
Newsroom
Gallery
Volunteer with Us
Careers at NCIS
Whistleblowing
I Want To
Make/Change/Cancel an Appointment
Find Directions
Find a Doctor
Find a Condition/Treatment
Contact NCIS
Pay Bills Online
Do a Search
×
Search
A
-
A
A
+
Home
>
For Healthcare Professionals
>
Journals and Publications
For Healthcare Professionals
Journals and Publications
Make a Referral
GP Liaison Centre
Research
Education
SPARK Newsletter
Journals and Publications
Journals and Publications
Page Content
Incredible Research @ NCIS
AccordionContent1
AABB 2024
Click here to read the paper:
Reducing Group and Crossmatch Errors in a Tertiary Academic Hospital in Singapore
ESMO 2024
Click for more info on presentations received by our NCIS clinicians at the European Society for Medical Oncology (ESMO) Congress 2024:
Pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
WCLC 2024
Click for more info on awards and presentations received by our NCIS clinician at the World Conference on Lung Cancer 2024:
IASLC Academy Award
ASCO Breakthrough 2024
Click for more info on awards and presentations received by our NCIS clinician at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting 2024:
A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA)
MASCC 2024
ISTH 2024
Click for more info on the presentations:
Low prevalence of cardiovascular risk factors in persons aged fifty years or younger with venous thromboembolism
Performance Of Chemiluminescence Assays for Laboratory Diagnosis of Antiphospholipid Syndrome – A Single Centre Experience
EHA 2024
Click for more info on the presentations:
FLAG-IDA + venetoclax (ven) in newly diagnosed (ND) or relapsed/refractory (RR) AML
Indirect treatment comparisons of daratumumab-pomalidomide-dexamethasone (DPD) and pomalidomide-bortezomib-dexamethasone (PVD) in relapsed/refractory multiple myeloma (RRMM)
Role of autologous stem cell transplantation in patients with primary CNS lymphoma: real-world data from a retrospective multi-centre analysis
ASCO 2024
Click for more info on the poster presentations:
Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immunerelated adverse events from immune checkpoint inhibitors
FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML
A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines
AACR 2024
Click for more info on the poster presentations:
CT160 – A phase I trial to evaluate allogenic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T cells in subjects with advanced solid tumors or haematological malignancies (the ANGELICA trial)
ASCO GI 2024
Click for more info on the poster presentations:
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center
Issue 3 - Dec 2021
Click for more info on the poster presentations:
Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study
HLA-Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back in Adults and Children with Hematological Malignancies: 4-Year Follow-up of Multicenter Study in Singapore
Cepp in Previously Untreated Patients with Mature T Cell Lymphomas
Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies
Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes
Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis
Graft-Vs-Host Disease (GvHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCy) and Thymoglobulin (ATG) Are More Important Determinants of Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Cell Transplantation (HCT) Than Ex-Vivo T-Cell Depletion in the Era of Pre-Emptive Therapy
Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Safety, Feasibility and Healthcare Cost Differences between Inpatient and Outpatient Mobilization Chemotherapy for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Single Center Experience
Issue 2 - Nov 2021
Click for more info on the research studies:
Determinants of response to Daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
International consensus guidelines on liver transplantation for non-resectable colorectal liver metastases
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
Issue 1 - Sep 2021
Click for more info on the poster presentations:
515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
1699P Introduction of the GOLDEN (Geriatric Oncology LongituDinal End to eNd) programme in a tertiary cancer centre
AccordionContent2
AccordionContent3
AccordionContent4
AccordionContent5
AccordionContent6
AccordionContent7
AccordionContent8
AccordionContent9
AccordionContent10
AccordionContent11
AccordionContent12
Quick Links
OneNUHS App
Our Patient Care Institutions
Find a Doctor
Getting to NCIS
Our Facilities
Our Services
Our Support Groups
Appointments
Events
Give a Gift
Newsroom
NUHS+ News Blog
Useful Links
Ministry of Health
Health Promotion Board
HealthHub
World Health Organisation
Agency for Integrated Care
Care to Go Beyond
Singapore Cancer Society
Contact Us
Feedback
Sitemap
Terms of Use
Personal Data Protection Act
Disclaimer
Privacy
Rate This Website
Report Vulnerability
Copyright © 2024 National University Health System.
All Rights Reserved.
Best viewed with IE 11, Chrome 79.0, Firefox 61.0, Safari 11
2024/10/22
